Market Overview

Prima BioMed Shares Rally Following New Outperform Rating, $6 Target At FBR

  • Shares of Prima BioMed Ltd (ADR) (NASDAQ: PNMD) are up 61 percent year-to-date, but still significantly below their 52-week high of $6.48.
  • FBR’s Vernon T. Bernardino initiated coverage of the company with an Outperform rating and a price target of $6.
  • The company has made significant advancement in enhancing its clinical stage product pipeline, Bernardiono noted.

Prima BioMed, which had only one active clinical program in 2014, has expanded and currently has three novel product candidates under active clinical development. Potential products from the company include IMP321, IMP731, and GSK 2831781, with the latter two rapidly under advancement by partners committed to their full evaluation.

“We believe the current valuation of Prima BioMed is disconnected from our estimation of the significant value PBMD has created in advancing its clinical-stage product pipeline,” analyst Vernon Bernardino mentioned.

Bernardino believes that the initiation of AIPAC, a planned Phase IIb combination study with paclitaxel and IMP321, will act as a significant catalyst for the stock. He added that positive AIPAC results could lead to full marketing authorization for IMP321 in the EU.

“[We] believe Prima’s next-generation approach in targeting checkpoint pathways is likely to generate significant partnership interest in the next 12 to 18 months,” the FBR report stated, while adding that the market for checkpoint modulators is witnessing continued growth.

Bernardino believes that IMP321 has blockbuster potential in breast cancer alone and expects it to gain approval in metastatic breast cancer as its first indication in 2020.

Latest Ratings for PBMD

Apr 2016Maxim GroupInitiates Coverage onBuy
Dec 2015Roth CapitalInitiates Coverage onBuy
Dec 2015FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for PBMD
View the Latest Analyst Ratings


Related Articles (PBMD)

View Comments and Join the Discussion!

Posted-In: FBR Vernon T. BernardinoAnalyst Color Long Ideas Initiation Analyst Ratings Trading Ideas

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at